Pharmacology, Toxicology and Pharmaceutical Science
Prodrug
100%
Dolutegravir
63%
Pharmacokinetics
53%
Integrase
34%
Human Immunodeficiency Virus 1
32%
Matrix Metalloproteinase
31%
Lamivudine
31%
Mouse
25%
Cabotegravir
23%
Biodistribution
21%
HIV
20%
Emtricitabine
20%
Mouse Model
15%
Rilpivirine
15%
Tenofovir
15%
Darunavir
15%
Surfactant
10%
Virus Transmission
9%
Infection
9%
Drug Concentration
8%
Adverse Event
8%
Neural Tube Defect
7%
Elimination
7%
Intramuscular Injection
6%
Clinical Trial
6%
Sprague Dawley Rat
6%
Drug Release
6%
Drug Formulation
6%
Chemicals and Drugs
5%
Chronic Disease
5%
Recombinant Antigen
5%
Virus Resistance
5%
Human Immunodeficiency Virus Infection
5%
Poloxamer
5%
Injection Site Reaction
5%
Tenofovir Alafenamide
5%
Keyphrases
Prodrug
55%
Nanocrystals
38%
Pharmacokinetic Profile
36%
ProTide
31%
Antiretroviral Therapy
27%
Human Immunodeficiency Virus Type 1 (HIV-1)
23%
Lipophilic
23%
Long-acting Parenteral
17%
Chemical Exchange Saturation Transfer Imaging
15%
Antiretroviral
15%
Cabotegravir
15%
Lamivudine
15%
Ultra-long
15%
Tenofovir
15%
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)
15%
Darunavir
15%
Triphosphate
15%
Humanized Mice
15%
Dolutegravir
15%
Monocyte-derived Macrophages
12%
Pharmacokinetics
11%
Cas9 Protein
9%
Lymphoid Tissue
9%
Sprague-Dawley Rats
8%
Drug Uptake
8%
Phosphoramidate Prodrug
7%
Drug Modification
7%
Antiretroviral Activity
7%
Treatment Limitation
7%
Nanoformulation
6%
Drug Levels
6%
Proviral DNA
6%
Tenofovir Alafenamide
6%
Hydrolysis
6%
Injection Site
6%
Muscle Injection
6%
Long-acting Antiretrovirals
5%
Drug Retention
5%
PADRE
5%
Modular Vaccines
5%
Clinical Translation
5%
CD4+ T Cells
5%
Site Frequency
5%
Local Injection Site Reaction
5%
Biocompatible Surfactants
5%
Single Treatment
5%
Intracellular Delivery
5%
Phosphoramidate
5%
Pronucleotides
5%